Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 5/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714888 | 0.87 | ADCY5 (0.67) | ADCY5PRMT5ADKWDR77 | |
| SCHEMBL19714842 | 0.86 | ADCY5 (0.48) | ADCY5PRMT5ADKWDR77 | |
| SCHEMBL25048759 | 0.83 | ADCY5 (0.42) | ADCY5PRMT5ADKWDR77METTL3 | |
| SCHEMBL19714848 | 0.80 | NEK2 (0.39) | ADCY5MEN1 | |
| SCHEMBL14447403 | 0.79 | MEN1 (0.43) | PRMT5ADKWDR77MEN1ABL1 | |
| SCHEMBL6045706 | 0.79 | ADCY5 (0.76) | ADCY5 | |
| SCHEMBL6045812 | 0.79 | ADCY5 (0.76) | ADCY5 | |
| SCHEMBL23584600 | 0.79 | ADCY5 (0.47) | ADCY5PRMT5ADKWDR77METTL3 | |
| SCHEMBL19344041 | 0.79 | ADCY5 (0.47) | ADCY5PRMT5ADKWDR77METTL3 | |
| SCHEMBL10236925 | 0.79 | ADCY5 (0.47) | ADCY5PRMT5ADKWDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | VASADE BIOSCIENCES, INC. | 2018-09-25 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | ADCY1, ADCY2, ADCY5 | ADCY5 3/4885PRMT5 783/4885ADK 94/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | ADCY5 3/4885PRMT5 783/4885ADK 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.